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Abstract
Background: The ability to achieve quality recovery of cell-
free foetal DNA is important for making non-invasive
prenatal diagnoses. In this study, we performed quantita‐
tive and qualitative analyses of isolated DNA from mater‐
nal plasma, using different DNA-isolation methods.
Method: DNA was isolated from 30 iso-immunized women
via the QIAamp column-based method, using four differ‐
ent elution volumes and two conventionally based meth‐
ods. Real-time polymerase chain-reaction quantification of
RHD and β-globin genes was performed in order to
determine foetal-specific sequences and total genome
equivalents, respectively.
Results: The column-based method at a 3 µl elution volume
yielded the highest quality and quantity of total DNA
(67.0±0.6 ng/µL). At a 3 µl elution volume, the β-globin and
RHD-gene sequences were estimated to be the highest
among all isolation procedures, with 2778.13±1.5 and
66.9±0.6 GEq/mL, respectively, and a 100% sensitivity for
RHD-gene sequence detection. Among the two conven‐
tional manual methods, the boiling lysis method yielded a
higher DNA concentration (53.8±0.8 ng/µL) and purity
(1.73±0.05). In addition, the method's sensitivity for foetal-
detection sequences was only 80%, whereas the salting-out
method's sensitivity was just 70%.
Conclusions: This study confirms the theory that the
QIAamp method is a specific and sensitive approach for
purifying and quantifying plasma DNA, when used in the
minimum elution volume.
Keywords Cell-free Foetal DNA, Plasma, Iso-immuniza‐
tion, Genome Equivalents, Elution Volume
1. Introduction
Maternal blood contains cell-free foetal DNA (cffDNA),
which is detectable as early as the sixth week of gestation;
its level rises during the advance of gestational age and
disappears rapidly after delivery [1]. Invasive procedures,
1J Circ Biomark, 2015, 4:12 | doi: 10.5772/62113
such as amniocentesis or chorionic villus sampling (CVS),
carry the risk of miscarriage as they rely on the sampling
of foetal tissues [2]. A consistent, convenient and reliable
method has been sought for prenatal diagnosis in order to
reduce this risk of miscarriage. The discovery of cffDNA in
plasma and serum had a wide application in non-invasive
prenatal diagnosis (NIPD), which ultimately reduced the
risk of foetal loss by a miscarriage. The many reported
applications off cffDNA include RHD genotyping [3–5],
foetal sexing [6], pregnancy-associated conditions such as
pre-eclampsia [7] and aneuploid detection [8]. The quality
recuperation of cffDNA in maternal plasma is key for non-
invasive prenatal diagnosis; however, limitations in
exploring cffDNA for NIPD include the associated recov‐
ery of maternal DNA and the failure to recover highly
purified cffDNA, both of which impede quantification
strategies and assay sensitivity [9]. As cffDNA represents
just 3–6% of the total cell-free DNA in maternal plasma, and
poses some technical difficulties in DNA extraction due to
its extremely low concentrations, an efficient DNA-
extraction method or technology is required [10].
To improve the yield of foetal DNA, various methods were
designed and formulated for the recovery of plasma from
maternal blood and the subsequent DNA isolation, as
plasma is considered to be a better source of foetal DNA
than maternal serum [11]. For efficient plasma-DNA
recovery, multiple methods of centrifugation and filtration
of plasma to remove apoptotic bodies and protein impuri‐
ties have been explored [9]. Commercial kits are used
widely to isolate DNA of medium- and large-molecular
sizes from body fluids, but less work has been done to
isolate and purify fragmented DNA and DNA with a low
molecular weight (about 50–150 bp). To improve the
quality and concentration of cffDNA, earlier studies have
compared manual methods to an automated DNA-
isolation system on the basis of sequence-specific copy
numbers [12, 13]. Differential elution volumes were used
in manual and automated DNA-isolation methods to
augment the concentration and foetal-detection sensitivity
[14]. Moreover, it was recently proposed that comparison
of manual, automated, or commercial DNA-isolation
methods increased the recognition, detection and predict‐
ability of foetal sequences, because observed concentra‐
tions of cffDNA differ depending on the processing and
analysis methods used [15, 12]. Due to these challenges, the
recovery of an optimal quantity of DNA and foetal-
detection markers remain both problematic and exigent.
Achieving this goal would pave a path for additional DNA-
isolation procedures that can enhance DNA concentration,
purity, throughput and efficacy in prenatal testing.
In this study, we have evaluated the suitability of three
different methods — one commercial method using
different elution volumes and two low-cost conventional
methods — by comparing the methods cffDNA yields in
terms of concentration, purity and the rate of detection of
foetal-specific sequences.
2. Materials and Methods
2.1 Subjects
The study was conducted in collaboration between the
Department of Obstetrics and Gynaecology and the
Department of Experimental Medicine and Biotechnology
of the Postgraduate Institute of Medical Education and
Research (PGIMER), Chandigarh, India. Gestational age
was calculated based on menstrual-cycle dates and was
confirmed by ultrasound. Where gestational age was not
certain, it was confirmed by ultrasound before 15 weeks of
gestation had passed. A cohort of 30 RHD-negative iso-
immunized women (length of gestation, 23–34 weeks),
whose foetus and partner were both RHD-positive, were
registered for the study. Pregnancies that experienced
intrauterine foetal death, foetal gross-congenital malfor‐
mations, multiple pregnancies and ones that had an RHD-
negative partner were excluded from the study. Full
written, informed consent was obtained from all the study
subjects prior to their participation. The Institute Ethics
Committee of PGIMER approved the study's protocol.
2.2 DNA extraction
From each subject, 10 ml of fresh blood was collected from
an antecubital vein via an EDTA vacutainer and was
transported the same day to the laboratory, where it was
kept at -4˚C and processed within 12 h. Plasma was
separated by centrifuging the samples at 3000 x g for 10
min. Isolated plasma was centrifuged again at 2000 x g for
7 min in order to remove the residual cells and leukocyte
carryover. The plasma samples were stored at -80°C before
further use. From each sample, 200 µL of plasma was used
in order to extract DNA for use in each method. In the
commercial column-based method, hereafter referred to as
a QIAamp-column method, DNA was extracted from 200
µL of plasma per column, using a QIAamp DNA Blood
Mini Kit (Qiagen; Hilden, Germany) according to the
“blood and body fluid protocol” [16] suggested by the
manufacturer, with a slight adjustment to accommodate
the higher plasma volume. The protocol was further
modified by incubating samples at 37°C for 2 h instead of
56°C for 10 min. DNA extracted via the commercial
column-based QIAamp method was finally eluted in four
different elution volumes using an AE elution buffer (50,
30, 10 and 3 µL) in order to check whether or not a modified
protocol combined with the use of different elution
volumes affects DNA concentration. This method is based
on the ability of DNA to bind to the silica surface of the
spin-binding column in a chaotropic salt solution after
proteinase K lysis has occurred. The second method,
hereafter referred to as Conventional Method 1 (CM1), was
performed according to the specifications of Miller et al.
[17] and involves proteinase K digestion, dehydration and
precipitation of proteins using a saturated NaCl solution,
followed by phenol:chloroform:isoamyl alcohol extraction
and ethanol precipitation. The DNA extracted using this
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method was eluted in 50 µL of nuclease-free water. The
third method involved the lysis of proteins in phenol-based
chaotropic salt by boiling samples at 58°C for 10 min,
followed by chloroform:isoamyl alcohol and isopropanol
precipitation, and 50 µL of nuclease-free water was used to
elute the extracted DNA. This method is hereafter called
Conventional Method 2 (CM2) [18]. One µL of the undilut‐
ed, extracted DNA sample was analyzed using a Nano‐
Drop ND-1000 spectrophotometer (NanoDrop
Technologies, Wilmington, DE) in order to check its purity
and concentration. The purity of the extracted DNA was
based on the A260:A280 optical density (OD) ratio, and elution
buffers used in each protocol were used as controls for OD
measures.
2.3 Real-time polymerase chain-reaction analysis
Quantitative real-time polymerase chain-reaction analysis
(q-PCR) was performed as previously described [19, 20],
with modifications to the PCR chemistry and target
primers. Eluted DNA from each method was analyzed via
a real-time q-PCR ABI 7500 detection system (Applied
BioSystems), using power SYBR® Green chemistry. The
PCR assay targeted RHD loci, a cell-free foetal DNA marker
[21] and β-globin gene loci. β-globin was used as an invariant
control and it differentiated between true-negative and
false-negative results deriving from a deficient DNA-
extraction process. Total DNA and cffDNA quantities were
represented as genome equivalents per millilitre (GEq/mL)
of plasma, based on copies of β-globin and RHD sequences
detected per microlitre of plasma. The RHD primer
sequence consists of a forward primer, 5’-CCT CTC ACT
GTT GCC TGC ATT-3’, and a reverse primer, AGT GCC
TGC GCG AAC ATT-3’, resulting in a 74 bp PCR product.
The β-globin primer sequence consists of a forward primer,
5´-GTG CAC CTG ACT CCT GAG GAG A-3´, and a reverse
primer, 5´-CCT TGA TAC CAA CCT GCC CAG-3´,
resulting in a 102 bp PCR product.
Amplification reactions were set up in a 25 µL reaction
volume consisting of a 10 µL power SYBR® Green PCR
Master Mix (Applied Biosystems) and 5 µL of template
DNA, in addition to primers. Primers were optimized in
order to determine the minimum primer concentrations
that give the maximum amount of normalized reporter.
Primers were used at the final concentration of 300 nM.
DNA amplification was carried out in 96 well plates
(Applied Biosystems). PCR conditions for all reaction
mixtures consisted of an initial denaturation step at 95°C
for 10 min and, finally, 40 cycles of 95°C for 15 s, 60°C for 1
min and 72°C for 30 s. Melting-curve analysis was carried
out at the end of each PCR assay in order to verify the
specificities of the amplified PCR products. An elution
buffer was used as a non-template control (NTC) and DNA
from a healthy RHD-positive individual was used as a
positive control in order to generate a standard curve using
10-fold dilutions (30000, 3000, 300, 30 and 3 GEq/mL) [21].
This standard curve was run in parallel with each PCR
reaction. All samples were analyzed in triplicate for both
genes, and the mean of the values was determined using
the 7700 software and the standard curve of known DNA
concentrations [9].
2.4 Statistical analysis
A Graph Pad Prism v5.0 (La Jolla, CA, USA) was used for
statistical analysis. For each parameter, the mean, the
standard error of the mean and the range were calculated.
Differences were evaluated via t-tests and non-parametric
Mann-Whitney tests, and values of p<0.05 were considered
to be statistically significant.
3. Results
To determine whether a difference in elution volumes
using the same method influences DNA's concentration
and purity, we checked four different elution volumes in
eluting the extracted DNA from plasma using the QIAamp
column-based method. As expected, DNA concentrations
and purities varied considerably between different elution















1.38±0.05 1.37±0.05 1.81±0.07 1.82±0.11 1.27±0.08 1.73±0.05
* Values are shown as mean with ± standard deviation (SD).
Table 1. DNA recovered from maternal plasma of RHD negative iso-
immunized women using different DNA isolation methods as measured by
spectrophotometer
Figure 1. Bar diagram showing a comparison of DNA concentrations
isolated from the maternal plasma of iso-immunized women using different
isolation procedures. (n=30). (*=50 µL QIAamp method) (#= 30 µL QIAamp
method) (α= 10 µL QIAamp method) (β= 3 µL of QIAamp method) (ψ=50
µL CM1); **p<0.01; ***p<0.001; #p<0.05, ###p<0.001; βββp<0.001; αp<0.05,
αααp<0.001.
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Figure 2. Bar diagram showing a comparison of the quality of DNA isolated
from the maternal plasma of iso-immunized women using different
isolation procedures. (n=30). (*=50 µL QIAamp method) (#= 30 µL QIAamp
method) (α= 10 µL QIAamp method) (β= 3 µL of QIAamp method) (ψ=50
µL CM1); **p<0.01; ***p<0.001; #p<0.05, ###p<0.001; βββp<0.001; αp<0.05,
αααp<0.001.
Among  the  four  different  elution  volumes,  the  3  µL
volume  yielded  a  significantly  higher  concentration  of
DNA (p<0.001)  as  compared to  the  three  other  elution
volumes. The DNA concentration derived using the 3 µL
volume was  3.36-  and 2.26-fold  higher  than  concentra‐
tions of the 50 and 30 µL volumes, respectively. Howev‐
er, there was only a 1.6-fold increase in DNA concentration
when compared to use of a 10 µL elution volume (p<0.001).
These  data  reveal  that  there  is  a  negative  correlation
between the elution volume used and DNA concentra‐
tion, as an increase in elution volume inhibits high DNA
concentration. The overall DNA yield was less while using
a 3 µL volume when compared with other volumes using
the same method (data not shown). This is probably due
to dilution of the sample, which decreases the elution's
efficiency.  Among the two conventional  methods,  CM1
yielded  a  1.82-fold  increase  in  DNA  concentration  as
compared to CM2 (p<0.001). CM1 proved useful only in
obtaining a 1.4-fold increase in DNA concentration when
compared with the QIAamp method using a 50 µL elution
volume.  However,  the  QIAamp  commercial  method
combined with 10 and 3 µL elution volumes increased the
DNA  concentration  by  1.2-  and  2.27-fold,  respectively,
when compared to CM1, and by 1.3- and 1.2-fold when
compared to CM2. These results show that a larger elution
volume decreases the overall DNA concentration, and vice
versa (Table 1, Figure 1).
The purity of the extracted DNA was counted as a measure
of the A260:A280 OD ratio using a NanoDrop spectropho‐
tometer, and that value is shown in Table 1, Figure 2. The
purified DNA sample was expected to show an A260:A280
ratio of 1.7 to 2.0. In a commercially based QIAamp method,
the best ratio was achieved using 10 µL (1.81±0.07) and 3
µL (1.79±0.11) elution volumes; however, this method did
not produce optimal ratios when using 50 or 30 µL vol‐
umes. Nor did CM1 produce an optimal ratio, suggesting
a partial precipitation of proteins reflecting an impure
DNA sample. Between the two conventional methods,
CM2 showed a significantly improved (p<0.01) A260:A280
ratio (1.73±0.05) as compared to CM1. Of all methods used,
the CM1 procedure was the least efficient DNA purity-
yielding method.
The β-globin gene was quantified via q-PCR in order to
determine the total GEq/mL, representing the total cell-free
DNA (maternal plus foetal DNA). The mean values are
shown in Table 2 with ±SD. Among the four different
elution volumes used in the QIAamp commercial method,
a higher β-globin concentration in terms of GEq/mL was
achieved (2778.13±1.5) by using a 3 µL volume as compared
to a 50 or 30 µL volume, which harvested mean concentra‐
tions of 2498.15±1.61 (p<0.001) and 2541.99±4.53 (p<0.001)
GEq/mL, respectively (Table 2). This accounts for around
1.11-fold (p<0.01) and 1.09-fold (p<0.05) increases in the β-
globin concentration compared to use of 50 or 30 µL
volumes, respectively. However, no significant increase in
the β-globin concentration for the 10 µL elution volume was
observed when compared with that of the 3 µL volume
(p>0.05). In the two conventional methods, CM1 slightly
increased the β-globin concentration, though to a non-
significant degree (p>0.05), which is contrary to the
spectrophotometric results. This anomaly might be due to
the generation of PCR inhibitors, which affects quantifica‐
tion of the β-globin.
When a QIAamp commercial method was compared with
both conventional methods, it proved to be more efficient
and significant (p<0.001) at increasing β-globin genome
equivalents, for all four elution volumes.
The quantity of cffDNA was determined by estimating the
RHD gene sequence for each isolation method (Table 2).
Comparison of the two conventional methods, CM1 and





































Table 2. DNA recovered from maternal plasma of RHD negative iso-immunized women using different DNA isolation methods as measured by real-time
polymerase chain reaction
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equivalents of RHD, with mean values of 65.7±1.09 and
65.1±0.2, respectively (p>0.05). In addition, the RHD
sequence detection-sensitivity rates were 70% (seven out of
10) and 80% (eight out of 10) for CM1 and CM2, respec‐
tively. Among the different elution volumes used in the
QIAamp commercial kit, the 3 µL volume yielded the
highest concentration (66.9±0.6) of the RHD sequences,
with 1.3-, 1.4- and 1.2-fold increases in the 50, 30 and 10 µL
volumes, respectively. However, the foetal-sequence
detection rate was 100% (10 out of 10) for all elution
volumes used in the QIAamp column-based method. The
concentration of the RHD gene sequences, determined in
terms of their genome equivalents, differed consistently
when compared with the β-globin genome equivalents.
When all methods are compared, the QIAamp commercial
kit method, used with a 3 µL elution volume, proved the
most efficient method for the detection of both β-globin
concentrations and RHD sequences.
4. Discussion
The recovery of quality DNA is necessary for proficient
molecular diagnostic and clinical investigation [22]. Due to
the presence of a small amount of foetal DNA that is
associated with complex proteins, the DNA-extraction
method needs to be optimized in such a way that the
maximum quantity of plasma DNA can be extracted with
the fewest impurities [1]. Hence, it is imperative to deter‐
mine which plasma DNA isolation and recovery methods
increase the efficiency, reliability and reproducibility of
foetal DNA extraction. To address this quality and quantity
issue, we tested three different methods for plasma DNA
isolation: the QIAamp commercial method and two
conventional methods. The QIAamp commercial method
was further tested for the issue of quality DNA recovery,
using four different elution volumes. The QIAamp com‐
mercial method, when used at a 3 µL elution volume,
proved to be the most efficient in terms of overall yield.
Using the QIAamp commercial method, we concluded that
DNA purity and concentration were at their maximum
when using the 3 µL elution volume; however, the detec‐
tion rates of total and foetal sequences were the same
(100%) for all elution volumes, although they differed in
achieving optimal DNA concentrations and purities. We
did find that using a small elution volume increases the
DNA concentration considerably, but also that it correlated
negatively with the DNA yield. In the QIAamp method,
our study demonstrated a negative correlation between the
elution volume, the purity and the quality of DNA and a
direct positive correlation between the purity of the
samples and the amount of total and foetal sequences
detected. These results are in accordance with early studies
carried out by Carolina et al. [9]. We achieved overall 3.3-
and 1.3-fold increases in DNA concentration and purity,
respectively, by using a 3 µL elution volume (Table 1). In
addition, total and foetal DNA sequences, measured using
real-time PCR, concomitantly increased by 1.1- and 1.3-
fold, respectively. These findings suggest that using a
smaller elution volume enhances the enrichment of total
DNA and small fragments of free foetal DNA. We also
observed a 4.8% reduction in Ct value in the q-PCR signal
for DNA isolated in a 3 µL elution volume as compared to
the three other elution volumes from the same method,
which indicates an increased quantity of DNA. This result
is supported by other findings showing that DNA eluted
while using a smaller amount of elution buffer gives an
early Ct value, indicating the presence of concentrated
DNA in the sample [23]. Elution carried out with the
smallest volume increased the final DNA concentration in
the elute, which is very important for any down-streaming
process. This result accords with other studies using
columns, indicating the ability of the column matrix to
enhance DNA concentrations while using a smaller elution
volume [24, 25]. However, using smaller elution volumes
led to a significantly lower DNA yield. The probable cause
for this result may be that the QIAamp column matrix in
the presence of the smallest elution volume might have
increased the ionic strength, which promoted the highest
DNA adsorption with the column matrix. The yield can be
improved significantly by eluting the DNA twice using the
same buffer; however, dilution renders lower cffDNA
quality/concentration, leading to false-negative PCR
results. None of the four elution volumes in the QIAamp
commercial method gave false-positive results, suggesting
the high specificity of this method for cell-free foetal DNA
isolation.
To determine the efficiency and reproducibility of the
QIAamp commercial method, we compared it with two
other conventional DNA-isolation methods, i.e., CM1 and
CM2, which are based on either the salting-out and
precipitation of proteins or the lysis of proteins by boiling,
respectively. CM2 produced an overall higher DNA yield
and quality (Table 1) than CM1. However, the total amount
of DNA measured by real-time PCR using the β-globin loci
in CM2 was lower than that of CM1. Partial protein lysis
and NaCl contamination (used for the precipitation of
proteins) could be the possible reason for the low purity
and small quantity of DNA in CM1; however, a non-
significant total DNA and foetal DNA sequence were
detected in CM2 than in CM1 (Table 2). A possible pro‐
posed reason might be the loss of smaller-size cffDNA
fragments, which might have developed due to an incre‐
mental temperature increase that was set up as 58°C for 10
min.
In summary, six different methods for the isolation of
cffDNA from the maternal plasma of RHD-negative iso-
immunized women were evaluated. A commercially
available QIAamp kit at a lower elution volume provides
optimal results for DNA purification with high sensitivity
and specificity. The resulting high-quality DNA should
facilitate precise quantification and sequence analysis, and
enable more efficient examination into the molecular
nature of the cffDNA in maternal plasma.
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